A Multicenter, Open-Label, Phase I/II Study Of EOS884448 In Combination With Standard Of Care And/Or Investigational therapies In participants With Advanced Solid Tumors Read more
A Phase 2 Study Of Erdafitinib In Subjects With Advanced Solid Tumors And Selected FGFR Gene Alterations. Read more
A Randomized Phase II/III Open-Label Study Of Ipilimumab And Nivolumab Versus Temozolomide In Patients With Actively Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma Read more
Treatment Of Actively Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) And Relapsed Favorable Histology Wilms Tumors (FHWT) Read more
A Phase 2, Open-Label Study Of Encorafenib + Binimetinib In Patients With BRAFV600E-Mutant Non-Small Cell Lung Cancer Read more
A Phase 1/2 Feasibility, Safety, And Activity Study Of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) In Subjects With Previously Treated Advanced Solid Tumors Read more
A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety And Activity Study Of Her-Targeted Dual Switch Car-T Cells (Bpx-603) In Subjects With Previously Treated Advanced Her2-Positive Solid Tumors Read more
Phase 1/2a First-In-Human Study Of BMS-986207 Monoclonal Antibody Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
Phase 1/2a First-In-Human Study Of BMS-986218 Monoclonal Antibody Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
